Cost-Effectiveness of Thrombolytics: A Simplified Model
- 66 Downloads
Objective of the study: To construct a simple model for an internal, retrospective cost-effectiveness analysis and to calculate the incremental cost-effectiveness of tissue plasminogen activator (TPA) over streptokinase (SK) in Turkey.
Setting: Koşuyolu Heart, Education and Research Hospital, Istanbul, Turkey.
Method: Among patients who were hospitalized for treatment of acute myocardial infarction (AMI), 196 were randomly selected. One-year mortality rates according to the treatment groups (TPA, SK, other) were determined. Among surviving patients, 28 from TPA and another 28 from SK group were randomly selected for the pharmacoeconomic analysis. Patient treatment data were taken from medical records while data regarding to costs were taken from hospital bills.
Main outcome measures: Incremental cost-effectiveness ratio (ICER). The cost part of the ratio was considered as ‘the overall-costs’, while the effectiveness part was considered as ‘lives saved’ per treatment group.
Results: With an increased one-year survival rate of 2.37% and an increased cost of €1120.8 ($1165.6) per patient in the TPA group, the ICER for the use of TPA instead of SK was €47,289 ($49,180.6) per life saved.
Conclusion: This model can be a guide for similar analyses. The results of our study (the incremental cost-effectiveness of TPA over SK) will be informative for the decision-makers in Turkey, by whom the medical benefit for money spent would be assessed and judged. We believe that our results make a contribution to similar studies in the literature.
KeywordsIncremental cost-effectiveness Pharmacoeconomic model Sensitivity analysis Streptokinase Thrombolytics Tissue plasminogen activator Turkey
Unable to display preview. Download preview PDF.
- The Thrombolysis Early in Acute Heart Attack Trial Study Group.1990Very early thrombolytic therapy in suspected acute myocardial infarctionAm J Cardiol654017Google Scholar
- Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group.1994Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patientsLancet34331122Google Scholar
- Basskin, LE. 1998Practical PharmacoeconomicsAdvanstarIndianapolisGoogle Scholar
- T.R. Prime Ministry-State Planning Organization. Long-Term Strategy and Eight Five-Year Development Plan 2001–2005. Ankara: 2001Google Scholar
- Levin, LA, Jönsson, B. 1992Cost-effectiveness of thrombolysis-a randomized study of intravenous rt-PA in suspected myocardial infarctionEur Heart J1328Google Scholar
- Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico.1987Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI studyLancet28714Google Scholar
- Baigent, C, Collins, R, fortheISIS Collaborative, Group. 1993ISIS-2: 4-year mortality follow-up of 17,187 patients after fibrinolytic and antiplatelet therapy in suspected acute myocardial infarctionCirculation881291Google Scholar
- Naylor CD, Bronskill S, Goel V. (1992). Reprint of ‘Canadian Consensus Conference on Coronary Thrombolysis’ – Part IV: EconomicsGoogle Scholar
- ISIS-3 (Third International Study of Infarct Survival) Collaborative Group.1992ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41299 cases of suspected acute myocardial infarctionLancet33975370Google Scholar
- The Gusto Investigators.1993An international randomized trial comparing four thrombolytic strategies for acute myocardial infarctionN Engl J Med32967382Google Scholar